The Australian company Invion met with the U.S. Food and Drug Administration to discuss the roadmap for their drug INV103, and the FDA agreed to its proposed indication of systemic lupus erythematosus. The company will be submitting an Investigational New Drug Application early in 2013.
INV103 is based on a naturally occurring protein, chaperonin10, which is present in all cells. It is thought to function as a natural regulator of the immune system. Administering the protein can help regulate inflammation, and can potentially be used to treat inflammatory diseases such as lupus.